David Espinoza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Espinoza has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- David M. Thomas
The University of New South Wales, Kensington, NSW, Australia
4 shared publications - Frank Lin
The Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
4 shared publications - John Simes
NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
4 shared publications - Mandy L. Ballinger
University of New South Wales
4 shared publications - Subotheni Thavaneswaran
NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
4 shared publications - Bruce A. Littlefield
Eisai Inc. 13 , Cambridge, Massachusetts
3 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (16) , 1-10
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program
Time-to-progression ratio (TTPr) measures intra-patient treatment benefit by comparing disease control on study treatment with that of the immediately preceding therapy. Its prognostic validity in the immune checkpoint inhibitor (ICI) era remains uncertain. We performed a pooled patient-level analysis of eight phase II trials. Associations between TTPr, TTP on prior therapy (TTP1), and on-study TTP (TTP2/ PFS), objective response rate (ORR), with overall survival (OS) were evaluated using Cox regression. Landmark analyses at 6-months were used to mitigate guarantee-time bias. Among 246 evaluable participants, median TTP1 and TTP2 were 3.9 and 2.1 months, respectively, with poor correlation (r = 0.02). TTPr was not associated with OS (TTPr ≥1.3 vs p < 0.001); (response vs non-response: HR 0.19, 95% CI 0.07-0.52, p = 0.001) and remained independently associated with OS in multivariable analyses. Findings were consistent across ICI and non-ICI trials. TTPr is not a robust prognostic measure in platform trials. Although this raises concern regarding its validity as a surrogate endpoint for OS, formal evaluation requires randomized treatment comparisons.
- 16 June 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (16) , 1-10
Open AccessTime-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program
Time-to-progression ratio (TTPr) measures intra-patient treatment benefit by comparing disease control on study treatment with that of the immediately preceding therapy. Its prognostic validity in the immune checkpoint inhibitor (ICI) era remains uncertain. We performed a pooled patient-level analysis of eight phase II trials. Associations between TTPr, TTP on prior therapy (TTP1), and on-study TTP (TTP2/ PFS), objective response rate (ORR), with overall survival (OS) were evaluated using Cox regression. Landmark analyses at 6-months were used to mitigate guarantee-time bias. Among 246 evaluable participants, median TTP1 and TTP2 were 3.9 and 2.1 months, respectively, with poor correlation (r = 0.02). TTPr was not associated with OS (TTPr ≥1.3 vs p < 0.001); (response vs non-response: HR 0.19, 95% CI 0.07-0.52, p = 0.001) and remained independently associated with OS in multivariable analyses. Findings were consistent across ICI and non-ICI trials. TTPr is not a robust prognostic measure in platform trials. Although this raises concern regarding its validity as a surrogate endpoint for OS, formal evaluation requires randomized treatment comparisons.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Purpose:Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies.Patients and Methods:Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1.Results:Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data.Conclusions:Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.See related commentary by Chen, p. 2130
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Purpose:Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies.Patients and Methods:Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1.Results:Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data.Conclusions:Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.See related commentary by Chen, p. 2130
- Open Access
- 5 May 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 103, 103090
Time trends in the incidence of multiple primary melanomas in Australia
- 5 May 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 103, 103090
Open AccessTime trends in the incidence of multiple primary melanomas in Australia
- Open Access
- 27 March 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 102, 103060
Prevalence and correlates of clinical skin checks for skin cancer among Australians
- 27 March 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 102, 103060
Open AccessPrevalence and correlates of clinical skin checks for skin cancer among Australians
- Open Access
- 22 March 2026
- Published by Elsevier in SSRN Electronic Journal
Time trends in the incidence of multiple primary melanomas in Australia
Background: The incidence of first primary melanoma has increased in many countries, but less is known about the incidence of multiple primary melanomas. We investigated trends in the incidence of multiple primary melanomas over time in Australia, and whether the trends differed by sex, age, and anatomical site.Methods: We examined the cumulative frequency and age-standardised incidence rates of second and higher-order primary melanomas in a population-based Australian cohort from seven cancer registries, comprising 299,535 individuals diagnosed with a first primary invasive melanoma between 1982 and 2016, and 221,973 individuals in a subset with a first invasive or in situ melanoma.Results: The age-standardised incidence rate of second primary invasive melanoma within 5 years of a first primary invasive melanoma increased for males from 4.7 (95% confidence interval (CI):3.3-6.1) per 1000 person-years in 1982-1986 to 9.7 (95% CI:8.3-11.1) per 1000 person-years in 2012-2016, and for females from 3.1 (95% CI:2.6-3.6) to 8.0 (95% CI:6.8-9.2) respectively. When in situ and invasive melanomas were considered together, the incidence rates surged from 7.0 (95% CI:5.0-8.9) to 29.5 (95% CI:18.0-41.0) per 1000 person-years for males and from 4.8 (95% CI:3.9-5.7) to 20.4 (95% CI:18.7-22.2) for females. Incidence trends over time were similar by sex and age-group but differed by anatomical site.Conclusions: Over three decades in Australia, age-standardised incidence rates for second primary melanoma approximately doubled for invasive melanoma and increased by four-fold when in situ melanomas were included. These findings highlight the need for strengthened prevention and early detection to manage this burden.
- 22 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTime trends in the incidence of multiple primary melanomas in Australia
Background: The incidence of first primary melanoma has increased in many countries, but less is known about the incidence of multiple primary melanomas. We investigated trends in the incidence of multiple primary melanomas over time in Australia, and whether the trends differed by sex, age, and anatomical site.Methods: We examined the cumulative frequency and age-standardised incidence rates of second and higher-order primary melanomas in a population-based Australian cohort from seven cancer registries, comprising 299,535 individuals diagnosed with a first primary invasive melanoma between 1982 and 2016, and 221,973 individuals in a subset with a first invasive or in situ melanoma.Results: The age-standardised incidence rate of second primary invasive melanoma within 5 years of a first primary invasive melanoma increased for males from 4.7 (95% confidence interval (CI):3.3-6.1) per 1000 person-years in 1982-1986 to 9.7 (95% CI:8.3-11.1) per 1000 person-years in 2012-2016, and for females from 3.1 (95% CI:2.6-3.6) to 8.0 (95% CI:6.8-9.2) respectively. When in situ and invasive melanomas were considered together, the incidence rates surged from 7.0 (95% CI:5.0-8.9) to 29.5 (95% CI:18.0-41.0) per 1000 person-years for males and from 4.8 (95% CI:3.9-5.7) to 20.4 (95% CI:18.7-22.2) for females. Incidence trends over time were similar by sex and age-group but differed by anatomical site.Conclusions: Over three decades in Australia, age-standardised incidence rates for second primary melanoma approximately doubled for invasive melanoma and increased by four-fold when in situ melanomas were included. These findings highlight the need for strengthened prevention and early detection to manage this burden.
- 2 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2206-2213
A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Purpose: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies. Patients and Methods: Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1. Results: Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data. Conclusions: Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity. See related commentary by Chen, p. 2130
- 2 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2206-2213
A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Purpose: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies. Patients and Methods: Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1. Results: Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data. Conclusions: Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity. See related commentary by Chen, p. 2130